

In treating a broad range of women with HR+/HER2- mBC:<sup>1</sup>

# CONFIDENCE BUILT ON STRENGTH

## NEW IBRANCE® (PALBOCICLIB) TABLETS NOW AVAILABLE FOR YOUR PATIENTS.






### New formulation. Same strength. Same confidence.<sup>1,2</sup>

IBRANCE is switching from capsule to tablet formulation with new packaging. It may take time for pharmacies to fully transition from capsules to tablets, so during this transition period, IBRANCE will be available in both tablet and capsule formulations.

**There is no change to the active ingredient** (palbociclib).<sup>1,2</sup>

**There is no change to the dosing schedule or dosage strength of IBRANCE** (125 mg, 100 mg and 75 mg doses will still be available).<sup>1,2</sup>

### Here's what's changing:<sup>1-4</sup>

Current Capsules			New Tablets		
21.7 mm	19.4 mm	18.0 mm	16.15 mm	15.00 mm	10.30 mm
					
125 mg	100 mg	75 mg	125 mg	100 mg	75 mg
Capsules and tablets have size indicated above.					
<b>Must be taken with food</b> (regardless of coadministration with PPIs or antacids when fasting reduces absorption by up to 62%)			<b>May be taken with or without food</b> (regardless of coadministration with PPIs or antacids), thus offering flexibility and convenience		
Contain lactose (dairy) and gelatin			Do not contain lactose or gelatin which may benefit those with dietary restrictions		
Gelatin coating on capsules			Film-coated tablets		
Capsules housed in portable blister packs			Tablets housed in portable blister packs with cycle tracker to help stay on schedule		



The blister packaging for IBRANCE will also change to include a cycle tracker, helping patients stay on schedule. Patients should be directed to take IBRANCE tablets immediately after removing them from the blister packaging.<sup>4</sup>

**IBRANCE®**  
palbociclib

### Indications:

IBRANCE is indicated for the treatment of patients with HR+/HER2- advanced or mBC:<sup>1</sup>

- In combination with an **AI as initial endocrine-based therapy**
- In combination with **fulvestrant in women with disease progression following ET**
- In **pre- or peri-menopausal women**, the combination of IBRANCE plus AI/fulvestrant should also be combined with an LHRH agonist

If you have any questions about the upcoming switch from capsules to tablets, please contact a Pfizer representative

### Required safety information

#### Full Prescribing Information

IBRANCE® (Palbociclib) Tablets Prescribing Information.

Available from: <https://labeling.pfizer.com/ShowLabeling.aspx?id=15902>

Scan QR Code for full prescribing information



To report any adverse events related to Pfizer pharmaceutical products, please contact us via:

**SGP.AEReporting@pfizer.com**

**AI** = aromatase inhibitor; **ET** = endocrine therapy; **HR+/HER2-** = hormone receptor-positive, human epidermal growth factor receptor 2-negative; **LHRH** = luteinising hormone-releasing hormone; **mBC** = metastatic breast cancer; **PPI** = proton pump inhibitor.

**References:** **1.** IBRANCE Film Coated Tablet Health Sciences Authority (HSA) – Approved Prescribing Information, Jan 2022. **2.** IBRANCE Capsule Health Sciences Authority (HSA) – Approved Prescribing Information, Jan 2022. **3.** Data on File. Size of Ibrance tablets. Pfizer Inc, New York, NY. **4.** Podsada K, et al. J Adv Pract Oncol. 2020;11(7):700–719.

#### For Healthcare Professionals only.

Pfizer Pte Limited. 80 Pasir Panjang Road, #16–81/82 Mapletree Business City, Singapore 117372

PP-IBR-SGP-0144/23FEB2022.

